Oramed Pharmaceuticals Inc. — Director's Dealing 2017

Aug 3, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2017-08-01

Reporting Person: Eisenberg Hilla (CFO, Treasurer and Secretary)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	1000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.77	2027-06-30	Common Stock (4500)		Direct
Stock Option (Right to Buy)	$8.57	2027-07-19	Common Stock (20001)		Direct

Footnotes

F1: The Stock Option will vest in 3 equal installments of 1,500 on each of December 31, 2017, December 31, 2018 and December 31, 2019.

F2: The Stock Option will vest in 3 equal installments of 6,667 on each of December 31, 2017, December 31, 2018 and December 31, 2019.